- Home
- / Rani Therapeutics
Rani Therapeutics
Stock Price
$2.3
2024-10-29
Market Capitalization
$135.4 M
2024-10-29
Revenue
$1.6 M
FY, 2025
Rani Therapeutics Summary
Company Summary
- Overview
- Rani Therapeutics Holdings is a clinical-stage biotherapeutics company developing technologies for orally administered biologics. It offers the RaniPill capsule, a platform technology for the oral delivery of large drug molecules, including peptides, proteins, and antibodies. Rani Therapeutics Holdings, Inc. operates through Rani Therapeutics, LLC.
- Type
- Public
- Status
- Active
- Founded
- 2012
- HQ
- San Jose, CA, US | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Mir Hashim, Chief Scientific Officer
Svai Sanford, Chief Financial Officer
Eric Groen, General Counsel
LocationsView all
1 location detected
San Jose, CA HQ
United States
2051 Ringwood Ave
Rani Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $1.7M
- Net income (Q1, 2026)
- ($7.0M)
- Cash (FY, 2025)
- $18.6M
- EBIT (Q1, 2026)
- ($8.3M)
- Enterprise value
- $133.6M